Sort
48,018 grants matching “immunotherapy”
Combinatorial application of nanoscale technologies to target a novel mechanism of immune evasion by cancer cells
$690,825Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2025 · CA
Administrative Core for SWOG SDMC
$690,792Michael Leo Leblanc · Fred Hutchinson Cancer Center · U10 · FY2025 · CA
Mapping and targeting 3D regulatory elements in leukemia and lymphoma
$690,772Iannis Aifantis · New York University School Of Medicine · R01 · FY2025 · CA
Innate Immune Mechanisms Contributing to Cancer Growth in Obesity
$690,624Edgar G. Engleman · Stanford University · R01 · FY2024 · CA
Adoptive Transfer of AlloCTL for Immunotherapy of Recurrent Gliomas
$690,480Carol A Kruse · University Of California Los Angeles · R01 · FY2011 · CA
Engineering knotted peptide therapeutics for pediatric brain tumor patients
$690,368James M Olson · Fred Hutchinson Cancer Research Center · R01 · FY2018 · CA
Biomarkers to Advance Clinical Phenotypes of Low Back Pain (BACk)
$690,319Adam Goode · Duke University · R01 · FY2023 · AR
Prostate Cancer Immunotherapy
$690,294Rockefeller University · R01 · FY2005 · CA
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
$690,258Diane M Simeone · New York University School Of Medicine · R01 · FY2021 · CA
Mechanisms for initiation of food allergy early in life
$690,169Joan M Cook-Mills · Indiana University Indianapolis · R01 · FY2021 · AI
Targeting extracellular vesicles in neuroblastoma
$690,013Vladimir S. Spiegelman · Pennsylvania State Univ Hershey Med Ctr · R01 · FY2025 · CA
A Phase 1 Study to Evaluate Chimeric Antigen Receptor (CAR) T cells Targeting TAG72 in Patients with Recurrent Epithelial Ovarian Cancer
$689,955Saul Priceman · Beckman Research Institute/City Of Hope · R01 · FY2023 · CA
Pediatric AIDS Clinical Trials Unit
$689,951Duke University · U01 · FY2003 · AI
Assessment of germline variants associated with immune-related adverse events following immune checkpoint inhibitors
$689,934Toni Choueiri · Dana-Farber Cancer Inst · R01 · FY2024 · CA
DEVELOPMENTAL FUNDS
$689,820Herbert Kim Lyerly · Duke University · P30 · FY2009 · CA
Clinical Protocol and Data Management (Core 018)
$689,776Elizabeth C Dees · Univ Of North Carolina Chapel Hill · P30 · FY2020 · CA
Blending deep learning with probabilistic mechanistic models to predict and understand the evolution and function of adaptive immune receptors
$689,648Frederick Albert Matsen · Fred Hutchinson Cancer Center · R01 · FY2024 · AI
Blending deep learning with probabilistic mechanistic models to predict and understand the evolution and function of adaptive immune receptors
$689,648Frederick Albert Matsen · Fred Hutchinson Cancer Center · R01 · FY2022 · AI
Optimizing the Graft-Versus-Tumor Effect in Allogeneic HSCT
$689,605Michael R Bishop · Clinical Sciences · Z01 · FY2007 · CA
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
$689,517Stephen C. Dreskin · University Of Colorado Denver · R01 · FY2022 · AI
Harnessing double stranded-RNA (dsRNA)-response and anti-tumor effect in PRC2-inactivated cancer
$689,468Ping Chi · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
$689,255Benjamin G. Neel · New York University School Of Medicine · R01 · FY2023 · CA
New Approaches to Modeling and Targeting Cyclin E-amplified High-Grade Serous Tubo-Ovarian Carcinoma
$689,255Benjamin G. Neel · New York University School Of Medicine · R01 · FY2022 · CA
Therapy Resistance Mechanisms for Cancer
$689,217Javed Khan · Division Of Basic Sciences - Nci · ZIA · FY2024 · CA
Eliminating the latent reservoir by targeted in vivo delivery of HIV-specific CARs
$689,181James L Riley · University Of Pennsylvania · R01 · FY2023 · AI